• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    5/12/23 9:06:47 AM ET
    $ABVC
    $ATNX
    $BBLN
    $BIOL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABVC alert in real time by email

    Gainers

    • Dermata Therapeutics (NASDAQ:DRMA) shares increased by 68.4% to $3.25 during Friday's pre-market session. The market value of their outstanding shares is at $2.7 million. The company's, Q1 earnings came out yesterday.
    • ARS Pharmaceuticals (NASDAQ:SPRY) shares moved upwards by 53.93% to $6.96. The market value of their outstanding shares is at $657.3 million.
    • Athenex (NASDAQ:ATNX) shares rose 20.68% to $1.4. The market value of their outstanding shares is at $12.1 million.
    • ABVC BioPharma (NASDAQ:ABVC) stock increased by 14.49% to $0.89. The market value of their outstanding shares is at $29.5 million.
    • Babylon Holdings (NYSE:BBLN) shares moved upwards by 14.28% to $1.36. The company's market cap stands at $33.8 million. As per the news, the Q1 earnings report came out 2 days ago.
    • PhenomeX (NASDAQ:CELL) shares increased by 12.19% to $0.92. The market value of their outstanding shares is at $90.8 million. The company's, Q1 earnings came out yesterday.

    Losers

    • Assure Hldgs (NASDAQ:IONM) shares decreased by 37.3% to $1.21 during Friday's pre-market session. The market value of their outstanding shares is at $1.3 million. As per the news, the Q1 earnings report came out 2 days ago.
    • Sunshine Biopharma (NASDAQ:SBFM) shares decreased by 22.23% to $0.7. The company's market cap stands at $15.8 million. As per the press release, Q1 earnings came out 2 days ago.
    • Impel Pharmaceuticals (NASDAQ:IMPL) shares decreased by 20.18% to $1.82. The company's market cap stands at $43.2 million. As per the news, the Q1 earnings report came out today.
    • Biolase (NASDAQ:BIOL) shares decreased by 16.55% to $0.2. The company's market cap stands at $5.2 million. As per the news, the Q1 earnings report came out yesterday.
    • Vyant Bio (NASDAQ:VYNT) stock fell 16.54% to $0.28. The company's market cap stands at $1.7 million.
    • Telesis Bio (NASDAQ:TBIO) stock decreased by 14.59% to $2.46. The company's market cap stands at $73.0 million. As per the news, the Q1 earnings report came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABVC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABVC
    $ATNX
    $BBLN
    $BIOL

    CompanyDatePrice TargetRatingAnalyst
    ARS Pharmaceuticals Inc.
    $SPRY
    11/4/2025$30.00Buy
    Roth Capital
    ARS Pharmaceuticals Inc.
    $SPRY
    9/4/2025$40.00Buy
    Roth Capital
    ARS Pharmaceuticals Inc.
    $SPRY
    3/7/2025$30.00Sector Outperform
    Scotiabank
    ARS Pharmaceuticals Inc.
    $SPRY
    2/10/2025$40.00Outperform
    Oppenheimer
    ARS Pharmaceuticals Inc.
    $SPRY
    8/20/2024Overweight
    Cantor Fitzgerald
    ARS Pharmaceuticals Inc.
    $SPRY
    8/13/2024$18.00 → $22.00Outperform → Strong Buy
    Raymond James
    ARS Pharmaceuticals Inc.
    $SPRY
    8/12/2024$19.00 → $20.00Outperform
    Leerink Partners
    ARS Pharmaceuticals Inc.
    $SPRY
    7/25/2024$18.00Outperform
    Raymond James
    More analyst ratings

    $ABVC
    $ATNX
    $BBLN
    $BIOL
    SEC Filings

    View All

    Sunshine Biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Sunshine Biopharma Inc. (0001402328) (Filer)

    2/20/26 4:08:43 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form PRE 14C filed by Sunshine Biopharma Inc.

    PRE 14C - Sunshine Biopharma Inc. (0001402328) (Filer)

    2/20/26 4:05:18 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Dermata Therapeutics Inc.

    SCHEDULE 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    2/18/26 4:49:52 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $ATNX
    $BBLN
    $BIOL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Ra Capital Management, L.P. bought $13,289,410 worth of shares (1,401,299 units at $9.48) (SEC Form 4)

    4 - ARS Pharmaceuticals, Inc. (0001671858) (Issuer)

    3/27/24 7:37:52 PM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Slilaty Steve N. bought $10,000 worth of Series B Preferred Stock (100,000 units at $0.10), increasing direct ownership by 333% to 130,000 units (SEC Form 4)

    4 - Sunshine Biopharma, Inc (0001402328) (Issuer)

    3/5/24 4:05:35 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Slilaty Steve N. bought $2,000 worth of Series B Preferred Stock (20,000 units at $0.10), increasing direct ownership by 200% to 30,000 units (SEC Form 4)

    4 - Sunshine Biopharma, Inc (0001402328) (Issuer)

    2/12/24 4:05:15 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $ATNX
    $BBLN
    $BIOL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital resumed coverage on ARS Pharmaceuticals with a new price target

    Roth Capital resumed coverage of ARS Pharmaceuticals with a rating of Buy and set a new price target of $30.00

    11/4/25 8:07:28 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Roth Capital initiated coverage on ARS Pharmaceuticals with a new price target

    Roth Capital initiated coverage of ARS Pharmaceuticals with a rating of Buy and set a new price target of $40.00

    9/4/25 7:57:34 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scotiabank initiated coverage on ARS Pharmaceuticals with a new price target

    Scotiabank initiated coverage of ARS Pharmaceuticals with a rating of Sector Outperform and set a new price target of $30.00

    3/7/25 8:14:43 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $ATNX
    $BBLN
    $BIOL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for FAMOTIDINE issued to ATHENEX INC

    Submission status for ATHENEX INC's drug FAMOTIDINE (SUPPL-13) with active ingredient FAMOTIDINE has changed to 'Approval' on 01/07/2022. Application Category: ANDA, Application Number: 075684, Application Classification: Labeling

    1/12/22 4:41:30 AM ET
    $ATNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for TRUDHESA issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/13/21 2:21:35 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DIHYDROERGOTAMINE MESYLATE issued to IMPEL NEUROPHARMA INC

    Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

    9/7/21 1:04:43 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $ATNX
    $BBLN
    $BIOL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences

    SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Monday, March 9, 2026 at 5:30 a.m. PT / 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and business highlights. Dial-in information for conference participants may be obtained by registering for the event. In addition, ARS Pharma Management will be participating at several upcoming investor conferences: 10th Annual Oppenheimer Emer

    2/23/26 8:00:00 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

    -Five poster presentations highlight clinical advancement of neffy, real-world usability and advantages of needle-free epinephrine delivery -Longer shelf life of nasal epinephrine compared with epinephrine auto-injectors translates into a more affordable, value-based price -When factoring in patients' dislike of needle-based administration, the value of a nasal option increased by more than 25% SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced today that five poste

    2/10/26 8:00:00 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg

    EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS Pharma's partner, ALK-Abelló A/S, who owns the rights to market EURneffy in the EU, will distribute following expected authorization by the European Commission SAN DIEGO, Feb. 02, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recomme

    2/2/26 8:00:00 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $ATNX
    $BBLN
    $BIOL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Sandler Andrew Seth

    4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)

    1/6/26 8:00:08 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Wierenga Wendell

    4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)

    1/6/26 8:00:11 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Senior VP, CDO Nardo Christopher J.

    4 - Dermata Therapeutics, Inc. (0001853816) (Issuer)

    1/6/26 8:00:08 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $ATNX
    $BBLN
    $BIOL
    Leadership Updates

    Live Leadership Updates

    View All

    ADARx Pharmaceuticals Appoints Industry Veteran, Laura Shawver, Ph.D., as Board Chair

    – Accomplished biopharma executive and entrepreneur brings a 25-year track record of upscaling valuable companies and realizing the potential of their innovations – SAN DIEGO, Sept. 17, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, today announced the appointment of Laura Shawver, Ph.D., as Chair of its Board of Directors. "We are honored to welcome Dr. Shawver to our Board. Laura's outstanding track record of driving strategic growth and developing innovative therapies comes at a pivotal time as we scale to advance our pipeline and expand the impact of our next-generation

    9/17/25 9:00:00 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer

    FORT LAUDERDALE, FL / ACCESSWIRE / January 15, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals is pleased to announce the appointment of Mr. Michel Roy as its new Chief Commercial Officer (CCO), effective immediately. Mr. Roy brings a wealth of experience and a proven track record of success in driving commercial growth and strategic initiatives.In this role, Mr. Roy will be responsible for overseeing the Company's commercial strategy, including sales, marketing, and business development. With over 20 years of experience in the pharmaceutic

    1/15/25 8:00:00 AM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

    Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024 and expands access to patients and caregivers managing Type 1 Allergic Reactions SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, announced today that Express Scripts, the pharmacy benefits business of Evernorth Health Services, has added neffy® (epinephrine nasal spray) to its Commercial national formularies. This decision makes neffy broadly available to millions of their commercially insured

    12/19/24 5:25:09 PM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $ATNX
    $BBLN
    $BIOL
    Financials

    Live finance-specific insights

    View All

    ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences

    SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Monday, March 9, 2026 at 5:30 a.m. PT / 8:30 a.m. ET to discuss its fourth quarter and full year 2025 financial results and business highlights. Dial-in information for conference participants may be obtained by registering for the event. In addition, ARS Pharma Management will be participating at several upcoming investor conferences: 10th Annual Oppenheimer Emer

    2/23/26 8:00:00 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)

    $32.5 million in revenue, including $31.3 million in neffy U.S. net product revenue in third quarter of 2025 Continued U.S. product growth driven by direct-to-consumer (DTC) investments and real-world evidence, expected to accelerate with seamless prescribing experience Strong balance sheet of $288.2 million cash, cash equivalents and short-term investments anticipated to fund operations through cash-flow break-even Conference call to be held today, November 10, 2025, at 5:30 a.m. PT / 8:30 a.m. ET  SAN DIEGO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better pro

    11/10/25 6:00:00 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results

    SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis, today announced the company will host a conference call and webcast on Monday, November 10, 2025, at 5:30 a.m. PT / 8:30 a.m. ET to discuss its third quarter 2025 financial results and business highlights. Dial-in information for conference participants may be obtained by registering for the event. To access the webcast and slides, please visit the Events & Presentations page in the Investors & Media section of the Company's website.

    11/3/25 8:00:00 AM ET
    $SPRY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVC
    $ATNX
    $BBLN
    $BIOL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ABVC BioPharma Inc.

    SC 13G/A - ABVC BIOPHARMA, INC. (0001173313) (Subject)

    11/14/24 7:33:18 PM ET
    $ABVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Dermata Therapeutics Inc.

    SC 13G/A - Dermata Therapeutics, Inc. (0001853816) (Subject)

    11/14/24 5:07:13 PM ET
    $DRMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sunshine Biopharma Inc.

    SC 13G/A - Sunshine Biopharma Inc. (0001402328) (Subject)

    11/14/24 4:28:14 PM ET
    $SBFM
    Biotechnology: Pharmaceutical Preparations
    Health Care